JP7825866B2 - ミトコンドリア増強療法 - Google Patents

ミトコンドリア増強療法

Info

Publication number
JP7825866B2
JP7825866B2 JP2022559816A JP2022559816A JP7825866B2 JP 7825866 B2 JP7825866 B2 JP 7825866B2 JP 2022559816 A JP2022559816 A JP 2022559816A JP 2022559816 A JP2022559816 A JP 2022559816A JP 7825866 B2 JP7825866 B2 JP 7825866B2
Authority
JP
Japan
Prior art keywords
cells
mitochondria
mitochondrial
enriched
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519744A (ja
JPWO2021199032A5 (https=
JP2023519744A5 (https=
Inventor
ナタリー イブギ－オハナ
ノア シェル
モリヤ ブラムキン
Original Assignee
ミノヴィア セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミノヴィア セラピューティクス リミテッド filed Critical ミノヴィア セラピューティクス リミテッド
Publication of JP2023519744A publication Critical patent/JP2023519744A/ja
Publication of JPWO2021199032A5 publication Critical patent/JPWO2021199032A5/ja
Publication of JP2023519744A5 publication Critical patent/JP2023519744A5/ja
Application granted granted Critical
Publication of JP7825866B2 publication Critical patent/JP7825866B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022559816A 2020-03-31 2021-03-29 ミトコンドリア増強療法 Active JP7825866B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063003174P 2020-03-31 2020-03-31
US63/003,174 2020-03-31
US202063118569P 2020-11-25 2020-11-25
US63/118,569 2020-11-25
PCT/IL2021/050349 WO2021199032A1 (en) 2020-03-31 2021-03-29 Mitochondrial augmentation therapy

Publications (4)

Publication Number Publication Date
JP2023519744A JP2023519744A (ja) 2023-05-12
JPWO2021199032A5 JPWO2021199032A5 (https=) 2024-04-09
JP2023519744A5 JP2023519744A5 (https=) 2024-04-09
JP7825866B2 true JP7825866B2 (ja) 2026-03-09

Family

ID=77928517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559816A Active JP7825866B2 (ja) 2020-03-31 2021-03-29 ミトコンドリア増強療法

Country Status (12)

Country Link
US (1) US20230338427A1 (https=)
EP (1) EP4125959A4 (https=)
JP (1) JP7825866B2 (https=)
KR (1) KR20220161326A (https=)
CN (1) CN115427052A (https=)
AU (1) AU2021248780A1 (https=)
BR (1) BR112022019432A2 (https=)
CA (1) CA3173425A1 (https=)
CO (1) CO2022013978A2 (https=)
IL (1) IL296786A (https=)
MX (1) MX2022012233A (https=)
WO (1) WO2021199032A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12329781B2 (en) 2018-07-22 2025-06-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
JP2021531288A (ja) 2018-07-22 2021-11-18 ミノヴィア セラピューティクス リミテッド 眼疾患のミトコンドリア増強療法
WO2020021536A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
JP7524157B2 (ja) 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法
CA3172402A1 (en) 2020-03-31 2021-10-07 Minovia Therapeutics Ltd. Mitochondria-enriched genetically engineered cells and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016135723A1 (en) 2015-02-26 2016-09-01 Minovia Therapeutics Ltd. Mammalian cells enriched with functional mitochondria
WO2020021540A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of pancreatic diseases
WO2020021539A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of muscle diseases
WO2020021536A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7524157B2 (ja) * 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016135723A1 (en) 2015-02-26 2016-09-01 Minovia Therapeutics Ltd. Mammalian cells enriched with functional mitochondria
JP2018507690A (ja) 2015-02-26 2018-03-22 ミノヴィア セラピューティクス リミテッド 機能性ミトコンドリアで富化された哺乳動物細胞
WO2020021540A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of pancreatic diseases
WO2020021539A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of muscle diseases
WO2020021536A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JACOBY E. et al.，First-in-Human Mitochondrial Augmentation of HematopoieticStem Cells in Pearson Syndrome，Blood，2018年，Vol.132(Supplement 1): 1024，https://doi.org/10.1182/blood-2018-99-113773

Also Published As

Publication number Publication date
JP2023519744A (ja) 2023-05-12
IL296786A (en) 2022-11-01
CA3173425A1 (en) 2021-10-07
EP4125959A1 (en) 2023-02-08
AU2021248780A1 (en) 2022-11-10
WO2021199032A1 (en) 2021-10-07
CO2022013978A2 (es) 2022-10-31
EP4125959A4 (en) 2024-07-10
CN115427052A (zh) 2022-12-02
US20230338427A1 (en) 2023-10-26
KR20220161326A (ko) 2022-12-06
BR112022019432A2 (pt) 2022-12-06
MX2022012233A (es) 2023-03-08

Similar Documents

Publication Publication Date Title
JP7825866B2 (ja) ミトコンドリア増強療法
US12605410B2 (en) Mitochondria-enriched genetically engineered cells and uses thereof
JP7633148B2 (ja) 機能的ミトコンドリアで富化された幹細胞を用いたミトコンドリア増強療法
JP2024138460A (ja) 原発性ミトコンドリア病のためのミトコンドリア増強療法
CN112481211A (zh) 免疫调节性提高的细胞及其使用和生产方法
JP2021532091A (ja) 膵臓疾患のミトコンドリア増強療法
JP2021532094A (ja) 筋疾患のミトコンドリア増強療法
WO2020021538A9 (en) Mitochondrial augmentation therapy of brain diseases
US20230392168A1 (en) Compositions and methods related to megakaryocyte-derived extracellular vesicles for treating myeloproliferative neoplasms
US20260102512A1 (en) Compositions and methods related to megakaryocyte-derived extracellular vesicles for fanconi anemia
CN116396940A (zh) 造血干祖细胞及其制备方法和用途
US20220184137A1 (en) Correction of Beta-Thalassemia Phenotype by Genetically Engineered Hematopoietic Stem Cell
JP2024546826A (ja) 骨髄異形成症候群のためのミトコンドリア増強療法
Xiong et al. Functional xenogeneic hematopoietic cells maintaining donor-dominant identity and immune tolerance enable therapy
CN117015552A (zh) 用于治疗骨髓增殖性肿瘤的与巨核细胞来源的细胞外囊泡相关的组合物和方法
Horwitz Future Directions in Pediatric Stem-Cell Transplantation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220929

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250512

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250513

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260217

R150 Certificate of patent or registration of utility model

Ref document number: 7825866

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150